Millions of Americans use GlaxoSmithKline’s purple inhaler. But whether Advair poses a higher risk of asthma-related death remains uncertain 15 years after regulators approved the drug. Advair is one of the biggest blockbusters in pharmaceutical history. The asthma drug has generated more than $80 billion in global revenues for its